Effect of pindolol on onset of action of paroxetine in the treatment of major depression: Intermediate analysis of a double-blind, placebo-controlled trial

American Journal of Psychiatry

Volumn 155, Issue 10, 1998, Pages 1346-1351

  Bordet, Régis ^a,b   Thomas, Pierre ^c   Dupuis, Bernard ^c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; PINDOLOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM;

EID: 0031710996     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.155.10.1346     Document Type: Article

References (33)

1. Boyer WF, McFadden GA, Feighner JP: The efficacy of selective serotonin reuptake inhibitors in depression, in Selective Serotonin Reuptake Inhibitors. Edited by Feighner JP, Boyer WF. Chichester, England, John Wiley & Sons, 1991, pp 89-108
2. Blier P, de Montigny C: Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994; 15: 220-226
3. Blier P, De Montigny C, Chaput Y: Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987;7:24S-35S
4. Hyttel J: Pharmalogical characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994; 9(suppl 1):19-26
5. Hoyer D, Clarke ED, Fozard J, Hartig P, Graeme M, Mylecharane E, Saxena P, Humphrey P: International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994; 46:157-203
6. Artigas F, Romero L, de Montigny C, Blier P: Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996; 19:378-383
7. Chaput Y, de Montigny C, Blier P: Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT auto-receptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1986; 333:342-348
8. Bel N, Artigas F: Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993; 15:243-245
9. Fuller RW: Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 1994; 55:163-167
10. Rutter JJ, Gundlah C, Auerbach SB: Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci Lett 1994; 171: 183-186
11. Heninger GR, Charney DS: Mechanism of action of antidepressant treatment: implication for the etiology and treatment of depressive disorders, in Psychopharmacology: The Third Generation of Progress. Edited by Meltzer HY. New York, Raven Press, 1987, pp 535-544
12. De Montigny C, Chaput Y, Blier P: Classical and novel targets for antidepressant drugs: new pharmacological approaches to the therapy of depressive disorders. Int Acad Biomed Drug Res 1993; 5:8-17
13. Bel N, Romero L, Celada P, de Montigny C, Blier P, Artigas F: Neurobiological basis for the potentiation of the antidepressant effect of 5-HT reuptake inhibitors by the 5-HT1A antagonist pindolol. Monit Mol Neurosci 1994; 6:209-210
14. Artigas F, Perez V, Alvarez E: Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors (letter). Arch Gen Psychiatry 1994; 51:248-251
15. Blier P, Bergeron R: Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995; 15:217-222
16. Berman RM, Darnell AM, Miller HL, Anand A, Charney DS: Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 1997; 154:37-43
17. Pérez V, Gilaberte I, Faries D, Alvarez E, Artigas F: Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997; 349:1594-1597
18. Tome MB, Isaac MT, Harte R, Holland C: Paroxetine and pindolol: a randomised trial of serotoninergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997; 12:81-89
19. Bordet R, Thomas P, Dupuis B: Selective serotonin reuptake inhibitors plus pindolol (letter). Lancet 1997; 350:289
20. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
21. Spitzer RL, Williams JBW, Gibbon M, First MB: User's Guide for the Structured Clinical Interview for DSM-III-R (SCID). Washington, DC, American Psychiatric Press, 1990
22. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
23. Bech P, Allerup P, Gram LF, Reisby N, Rosenberg R, Jacobsen O, Nagy A: The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand 1981; 63:290-299
24. Conners CK, Barkley RA: Rating scales and checklists for child psychopharmacology. Psychopharmacol Bull 1985; 21: 809-843
25. Hirschfeld RMA: Guidelines for the long-term treatment of depression. J Clin Psychiatry 1994; 55(Dec suppl):61-69
26. Dumon J-P, Catteau J, Lanvin F, Dupuis BA: Randomized, double-blind, crossover, placebo-controlled comparison of propranolol and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1992; 149:647-650
27. Bailly D: The role of beta-adrenoreceptor blockers in the treatment of psychiatric disorders. CNS Drugs 1996; 5:115-136
28. Avorn J, Everitt DE, Weiss S: Increased antidepressant use in patients prescribed β-blockers. JAMA 1986; 255:357-360
29. Tricklebank MD, Forler C, Fogard JR: The involvement of sub-types of the 5-NT1 receptor and of catecholaminergic systems in the behavioral response to 8-hydroxy-2-(di-n-propylamino) tetralin in the rat. Eur J Pharmacol 1984; 106:271-282
30. Artigas F: 5HT and antidepressants: new views from microdialysis studies. Trends Pharmacol Sci 1993; 15:262-263
31. Hjorth S: Serotonin 5HT1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminals output of 5-HT in vivo: a microdialysis study. J Neurochem 1993; 60:776-779
32. Kreiss DS, Lucki I: Desensitization of 5-HT1A autoreceptors by chronic administration of 8-OH-DPAT. Neuropharmacology 1992; 31:1073-1076
33. Pineyro G, Blier P, Dennis T, De Montigny C: Desensitization of the neuronal 5-HT carrier following its long-term blockade. J Neurosci 1994; 14:3036-3047